Royal Bank Of Canada reaffirmed their sector perform rating on shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) in a research note published on Monday morning, StockTargetPrices.com reports. The firm currently has a C$38.00 price objective on the specialty pharmaceutical company’s stock.
Several other research analysts also recently weighed in on the company. Scotiabank reaffirmed a sector perform rating and set a C$17.00 target price on shares of Valeant Pharmaceuticals Intl in a research note on Wednesday, January 11th. Morgan Stanley downgraded Valeant Pharmaceuticals Intl from an overweight rating to an equal weight rating in a research note on Thursday, December 15th. Finally, TD Securities reduced their target price on Valeant Pharmaceuticals Intl from C$38.50 to C$18.00 and set a hold rating for the company in a research note on Thursday, November 10th.
Valeant Pharmaceuticals Intl (TSE:VRX) opened at 19.86 on Monday. The company’s market capitalization is $6.90 billion. The firm has a 50-day moving average of $19.92 and a 200 day moving average of $28.35. Valeant Pharmaceuticals Intl has a one year low of $17.42 and a one year high of $142.35.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).